Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 107

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 107
---
ing or period that services will be provided for all time-based awards. Share-based compensation expense for the years
ended December 31, 2024 and 2023 was comprised of the following:

    Schedule of share-based compensation expense 

    Year Ended December 31, 2024  
    Year Ended December 31, 2023 
  
    Research and development 
    $4,867  
    $21,935 
  
    General and administrative 
     –  
     – 
  
    Total 
    $4,867  
    $21,935 

The following summarizes our transaction activity
related to RSUs for the year ended December 31, 2024:

    Schedule of RSU activity 

     Shares  
    Weighted Average Grant Date Fair Value 
  
    Nonvested at January 1, 2024 
     541,957  
    $3.01 
  
    Granted 
     –  
     – 
  
    Vested 
     –  
     – 
  
    Forfeited 
     (31,444) 
     (3.21)
  
    Nonvested at December 31, 2024 
     510,513  
    $3.00 

As of December 31, 2024, there was no unrecognized
compensation cost related to RSUs. As of December 31, 2024, 14,044 RSUs have vested under the 2020 Plan since its adoption.

10.        Income Taxes

The provision (benefit) for income taxes for the years ended December
31, 2024 and 2023 is as follows:

    Schedule of provision (benefit) for income
    taxes 

    Year Ended
                                                                                December 31, 2024  
    Year Ended
                                                                                December 31, 2023 
  
    Current: 

    Federal 
    $–  
    $– 
  
    State 
     2,400  
     2,400 
  
    Total current 
     2,400  
     2,400 

    Deferred: 

    Federal 
     –  
     – 
  
    State 
     –  
     – 
  
    Total deferred 
     –  
     – 

    Total provision 
    $2,400